Richard has more than 30 years continuous working experience in private practice. He has encountered a broad and varied spectrum of possible situations and scenarios involving all sorts of IP challenges and requirements.
Certain essential elements of patent work align well with Richard's character. He enjoys the sense of chase he gets in fact finding and "stone turning". This means Richard is very adept at peeling back the layers of any matter to get quickly to the heart of it, legally, technically and commercially. He also has a particularly well-honed radar for identifying risk and opportunity, and then a creative imperative and internal driver to match. Richard finds the combinations of these skills serves him well in generating excellent cost effective commercial solutions to whatever patent challenges he is presented with.
Broadly, Richard's technical knowledge and experience comes under IPC codes: A01, A21, A22, A23, A24, A61, B01, B09, B82, C02, C04, C11, C12 (C12N, C12 Q), C13, C25 and C40.
More specifically: CRISPR; gene editing; riboswitches, nucleic acid sequencing; PCR based assays; nucleic acid-based diagnostics; antibodies (therapeutic or diagnostic), immunoaffinity purification; chimeric T cells and therapies; miRNA, siRNA, oncology; biomarkers; bioinformatics; enzymes; epigenetics; modified bacteria, viruses, algae, fungi, plants, insects (mosquitoes), fish and fish feed, animals, plant secondary compounds; oligosaccharides; pest control; plant breeding tools; plant protection products; biodegradable packaging; sewage treatments; human pharmaceutical formulations (small molecules, proteins, antibodies); vaccines (anticancer, influenza); medical devices; ocular devices, diagnostics and therapies.
Natural Science (Oxon)
Patent Litigation (Nottingham Trent)
Plant Science (Wales)
“…excellent knowledge, experience and analytical acumen…”. (Legal 500 - 2011) “…superb…”’ (Legal 500 - 2012)
November 28th 2019
November 28th 2019
June 3rd 2019
Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …Read article
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …Event details
HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …Event details
HGF Patent Attorney Dr Robert Weinert-Aplin is attending and speaking at the Manufacturing & Supply Chain Conference on 10th March 2022 in Milton Keynes, UK. The Manufacturing & Supply Chain …Event details
HGF Partner and Patent Attorney Craig Thomson and Patent Director Dr Jennifer Bailey write an article for The Microbiome Times on ELIGO v SNIPR: a reflection on IP strategies in …Read article
With news that the Austrian parliament has ratified the Protocol on the provisional application of the Agreement on a Unified Patent Court on 2 December 2021, the Unified Patent Court …Read article
If you would like to discuss how HGF could help you, contact one of our IP specialists.